Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, on how the recent National Coverage Determination for Next Generation Sequencing is relevant to the treatment of NSCLC

Published: 16 April 2018

Recent Videos: Diagnostics (includes Molecular Diagnostics)

There have been no new videos in this category within the last 12 months.

Related Videos

video-image

Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC - Dr. Walter Stadler

video-image

Nicolas Ferreyros, on the influence of pharmacy benefit managers

video-image

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

video-image

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

video-image

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

video-image

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

video-image

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

video-image

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

video-image

Anshu Jain, MD, on the current controversy regarding proton therapy in cancer care

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Anshu Jain, MD, explains why proton therapy is important in terms of delivery & outcomes

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares how COA is supporting Dayton Physicians Network

video-image

Matthew Hall, MD, tells us what physicians & payers should know about proton therapy

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares key takeaways from the 2019 COA Annual Conference

video-image

Matthew Hall, MD, considers whether the application of proton therapy is growing

video-image

Lakshmi Aggarwal, MD, explains why transparency is necessary in the healthcare system

video-image

Matthew Hall, MD, on the difference between photon therapy & proton therapy

video-image

Lakshmi Aggarwal, MD, considers the role of politics in oncology

video-image

Lucio Gordan, MD, shares how the shift in site of care is impacting community oncology

video-image

Lakshmi Aggarwal, MD, offers opinion on the evolving landscape of oncology

video-image

Lucio Gordan, MD, explains how practices should leverage their OCM performance data

video-image

Jesse Dresser evaluates the impact of payer trends on drug manufacturers' market access strategy

video-image

Lucio Gordan, MD, on best practices in delivering value-based care

video-image

Jesse Dresser shares what legal tools are available to dispensing oncology practices & pharmacies

video-image

Lucio Gordan, MD, describes the primary drivers of the cost of cancer care

video-image

Jesse Dresser considers the challenges for dispensing oncology practices regarding payer networks

video-image

Kathy Gaughran explains how Healthcare Success is helping community oncologists

video-image

Jesse Dresser on the trends he is observing between payers and dispensing practices & pharmacies

video-image

Bobbi Buell, MBA, regarding the biggest changes & challenges in oncology reimbursement in 2019

video-image

Sibel Blau, MD, on the pros & cons associated with participation in a clinically integrated network

video-image

Sean Brusky explains how the pharmaceutical industry is working to help community oncology

video-image

Sibel Blau, MD, elaborates on clinically integrated networks

video-image

Sean Brusky provides Genentech’s perspective on the rising cost of cancer drugs and patient access

video-image

Sibel Blau, MD, tells us more about IQ Oncology

video-image

Sean Brusky on taking value into consideration when developing cancer drugs

video-image

Sibel Blau, MD, shares what the QCCAN is doing for participating members

video-image

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

video-image

Michael Diaz, MD, regarding high priority policy initiatives for COA

video-image

Michael Diaz, MD, articulates his goals for the coming year as president of COA

video-image

Michael Diaz, MD, shares exciting updates from the 2019 Community Oncology Conference

video-image

Stephen Schleicher, MD, MBA, regarding participation in a two-sided risk model

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Stephen Schleicher, MD, MBA, on the challenges associated with value-based care

video-image

Alexander Spira, MD, PhD, FACP, tells us the latest thinking regarding the PD-L1 biomarker

video-image

Russell Gollard, MD, offers opinion on why IDNs are a cancer delivery model of the future

video-image

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

video-image

Russell Gollard, MD, considers the difference between a hospital and a non-hospital IDN

video-image

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

video-image

Russell Gollard, MD, considers the main impediments to coordinated care

video-image

Russell Gollard, MD, explains how IDNs effectively coordinate cancer care

video-image

Andrew Hertler, MD, FACP, on measuring success in value-based cancer care delivery

video-image

Andrew Hertler, MD, FACP, offers advice to oncology practices entering the value-based world

video-image

Andrew Hertler, MD, FACP, considers the benefits of participating in an ACO

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

video-image

James Hamrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hamrick, MD, discusses the value of real world evidence data

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Ted Okon, MBA, offers his interpretation of the Practice Impact Report released at COA 2018

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Robert Rifkin, MD, tells us about biosimilar pricing and reimbursement

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Rebecca A. Kirch, JD, on factors that should be considered before starting a palliative care program

video-image

Rebecca A. Kirch, JD, discusses the impact of high quality palliative care programs

video-image

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Miriam Atkins, MD, considers what COA is doing to educate patients on their cancer care

video-image

Michael Kolodziej, MD, FACP, on the legislative issues most salient to community oncologists today

video-image

Michael Kolodziej, MD, FACP, considers how the move from volume to value impacts community oncology

video-image

Mark Fendrick, MD, on cost containment strategies that work best in value-based insurance design

video-image

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Michael Diaz, MD, shares what COA is doing to educate cancer care patients

video-image

Michael Diaz, MD, tells us about the goals of the patient initiative on Capital Hill at COA 2018

video-image

Kathy Oubre on how lobbying has helped influence the community oncology agenda

video-image

Kathy Oubre outlines some of the lobbying tactics that community oncology practices should adopt

video-image

Kathy Oubre explains why it’s important for community oncology practices to participate in lobbying

video-image

Jonathan E. Levitt, Esq. explains why oncology practices should be aware of co-pay aggregators

video-image

Jonathan E. Levitt, Esq. on the importance of PBM transparency

video-image

Jonathan E. Levitt, Esq. discusses the problems that exist between PBMs and oncology providers

video-image

Jonathan E. Levitt, Esq. provides an update on the oncology landscape from a legal perspective

video-image

Jeff Mortier explains what can be done to encourage PBM transparency

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Jeff Mortier discusses some of the issues presented at Hill Day during COA 2018

video-image

Fred Schnell, MD, compares OCM 2.0 and OCM 1.0

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Fred Schnell, MD, considers why practice transformation is often difficult in oncology

video-image

Debra Patt, MD, MPH, MBA, regarding advances in next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, considers reimbursement & coverage of CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on what community oncologists should know before prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, explains the benefits & challenges associated with prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, analyzes the logistics associated with CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on CMS’s National Coverage Determination & next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, regarding the reliability of next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, on the progress being made in next-generation sequencing

video-image

Bud Pierce, MD, describes how Oregon Oncology Specialists has evolved

video-image

Bud Pierce, MD, explains what his practice is doing to alleviate financial toxicity

video-image

Bud Pierce, MD, regarding the doctor-patient relationship in today’s oncology landscape

video-image

Brian DeLashmutt considers cost of care in hospital-based & community oncology settings

video-image

Brian DeLashmutt shares details of his own cancer care experience

video-image

Houston Holmes, MD, MBA, FACP, provides perspective on reimbursement & coverage of CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on what community oncologists should know about prescribing CAR-Ts

video-image

Houston Holmes, MD, MBA, FACP, regarding the benefits & challenges of prescribing CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on the logistics associated with CAR-T therapies

video-image

Suanne Gersdorf, FACHE, MSB, on the impact of value-based care and easing financial toxicity

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Suanne Gersdorf, FACHE, MSB, considers how EHR data can be used to improve outcomes

video-image

Suanne Gersdorf, FACHE, MSB, on how oncology practices have become more efficient in utilizing APNs

video-image

Suanne Gersdorf, FACHE, MSB, regarding the importance of embracing APNs

video-image

Harry “Mac” Barnes, MD, explains the benefits of training advanced practitioners

video-image

Harry “Mac” Barnes, MD, elaborates on the role of advanced care providers in cancer patient care

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Jennie Crews, MD, MMM, FACP, on the influence of MIPS & MACRA at Seattle Cancer Care Alliance

video-image

Satish Shah, MD, on how technology can ease the burden of reporting quality measures

video-image

Kavita Patel, MD, MS, FACP, discusses how 340B has impacted her practice

video-image

Kavita Patel, MD, MS, FACP, regarding the impact of MACRA on payment reform

video-image

Stephen Grubbs, MD, considers how MIPS & MACRA are transforming the delivery of cancer care

video-image

Stephen Grubbs, MD, describes the tools ASCO provides to help practices move toward value-based care

video-image

Stephen Grubbs, MD, on what ASCO is doing to help educate members about MIPS & MACRA

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Ann Marie Edwards on how patients have been impacted by value-based care

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Ann Marie Edwards examines how 340B has impacted Alliance Cancer Specialists

video-image

Ann Marie Edwards considers the physician practice models poised to succeed in a value-based world

video-image

George Daneker, MD, on the role of CMS and commercial payers in delivering value-based care

video-image

George Daneker, MD, regarding the role of consistency in the delivery of high-quality care

video-image

Jennie Crews, MD, MMM, FACP, on embracing new value-based oncology models

video-image

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

video-image

Sibel Blau, MD, discusses how 340B has impacted Northwest Medical Specialties

video-image

Sibel Blau, MD, shares how her practice has transformed in order to participate in MACRA

video-image

Roy Beveridge, MD, regarding the most cost-efficient alternative payment models

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents

video-image

Ray Bailey explains how he works with payers to dispense oral cancer agents to patients

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system

video-image

Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting

video-image

Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care

video-image

Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system

video-image

Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data

video-image

Bobbi Buell offers advice to practices on how to guarantee good coding

video-image

Bobbi Buell on the implications of mistakes in coding

video-image

Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology

video-image

Bruce Feinberg, DO, shares his special interest in value-based care

video-image

Bruce Feinberg, DO, comments on site of care and its impact on cancer economics

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, reflects on how his practice manages the transition to value-based care

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Edward Li considers how comfortable medical oncologists and patients should be with biosimilars

video-image

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

video-image

Edward Li outlines the legal challenges surrounding biosimilars and market entry

video-image

Edward Li on the status of the biosimilars regulatory pathway

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive

video-image

Ben Jones on the hot policy topics impacting the delivery of quality cancer care

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

video-image

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

video-image

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges

video-image

James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow

video-image

James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care

video-image

Matt Farber describes how specialty pharmacies differ

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

Skip Burris, MD, offers his opinion on searching for rare mutations

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Bobbi Buell explains how practices can avoid the most common mistakes in billing

video-image

Skip Burris, MD, offers his opinion on molecular profiling patients

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

Brad Prechtl explains how “shared savings” works between FCS and a local payer

video-image

Brad Prechtl on the keys to success for Florida Cancer Specialists

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

William Harwin, MD, describes the shift from fee for service to value-based care

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA

video-image

Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings

video-image

Ricky Newton provides an example of how a PBM is impacting cancer patient care

video-image

Ricky Newton describes the paper COA is releasing on patient experiences with PBMs

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Bobby Green, MD, explains how he defines big data

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Barbara McAneny, MD, discusses novel payer initiatives she finds interesting

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Ed Bassin, Ph.D., on if there will be health care savings with the implementation of the OCM

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Michael Kolodziej, MD, describes the breadth and depth of alternative payment models

video-image

Michael Kolodziej, MD, tells us why alternative payment models are needed

video-image

Kavita Patel, MD, MS, explains how 340B is impacting cancer care

video-image

Kavite Patel, MD, MS, tells us whether ACOs are having an impact on oncologists

video-image

Michael Kolodziej, MD, discusses alternative payment models of the future

video-image

John Iacuone, MD, MBA, explains how practices stay independent in pay for performance environment

video-image

Bobby Green, MD, MSCE, explains the frustrations with data coming from oncology practices

video-image

Kavita Patel, MD, MS discusses how important cancer care management is to Medicare

video-image

William Harwin, MD, gives his opinion if practices can survive in today's value based environment

video-image

John Sprandio, MD, explains how his practice worked with CMS to help develop the Oncology Care Model

video-image

Harold Miller discusses the barriers in the fee for service model